ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Jasmeet Kaur

Provisional: name at one institution (moderate confidence)As of 11 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Papers: 0
Trials: 2 (principal investigator on 2)
Grants: 0
Collaborators: 0

Papers, trials and grants by year

2019: 1 trial · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 trial

Trials 2

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Principal investigator NCT06202066 ↗
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Principal investigator NCT03879694 ↗

Closest collaborators

No collaborators recorded.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.